News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Appeals Court Invalidates Bristol-Myers Squibb Company (BMY)'s Hepatitis B Patent, Backs Teva Pharmaceutical Industries Limited (TEVA)



6/13/2014 6:13:21 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

U.S. Court of Appeals Denies Appeal in Baraclude Patent Case

NEW YORK, Jun 12, 2014 (BUSINESS WIRE) -- Bristol-Myers Squibb Company BMY -0.17% today announced that the U.S. Court of Appeals for the Federal Circuit has denied the company’s appeal of a February 2013 ruling by the U.S. District Court for the District of Delaware that found the patent covering Baraclude (entecavir), U.S. patent 5,206,244 invalid.

The company is reviewing the decision and considering all its legal options.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews .

SOURCE: Bristol-Myers Squibb Company

Bristol-Myers Squibb
Media
Frederick Egenolf, 609-252-4875
frederick.egenolf@bms.com
or
Investor Relations
Ryan Asay, 609-252-5020
ryan.asay@bms.com
Ranya Dajani, 609-252-5330
ranya.dajani@bms.com

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES